Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Breast 1

Conditions

Prostatic Neoplasms 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Docetaxel 19pembrolizumab 14Surveys and Questionnaires 7Radiotherapy 7Paclitaxel 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Standard of Care 6Specimen Handling 6Radiosurgery 6Psychiatric Rehabilitation 6Early Intervention, Educational 6Trastuzumab 5Nivolumab 5enzalutamide 4Interviews as Topic 4motexafin gadolinium 3cabozantinib 3X-Rays 3Sirolimus 3Methods 3Educational Status 3Cisplatin 3Carboplatin 3Azacitidine 3tisotumab vedotin 2rucaparib 2pertuzumab 2pegilodecakin 2palbociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Technetium Tc 99m Medronate × Thoracic × Clear all
NCT05614518 2022-11-14

Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT

HTA Co., Ltd.

Phase 3 Completed
280 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡